American Association for Cancer Research
crc-22-0419_fig3.png (656.91 kB)

FIGURE 3 from Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project

Download (656.91 kB)
posted on 2023-10-10, 14:20 authored by Alexander Semaan, Vincent Bernard, Justin Wong, Yuki Makino, Daniel B. Swartzlander, Kimal I. Rajapakshe, Jaewon J. Lee, Adam Officer, Christian Max Schmidt, Howard H. Wu, Courtney L. Scaife, Kajsa E. Affolter, Daniela Nachmanson, Matthew A. Firpo, Michele Yip-Schneider, Andrew M. Lowy, Olivier Harismendy, Subrata Sen, Anirban Maitra, Yasminka A. Jakubek, Paola A. Guerrero

Inferred evolutionary trajectory derived from CNAs. Cases showing linear (A) and branched (B) evolution are depicted. For each case, evolutionary tree and segmentation plots are shown with HapLOHseq calls represented in lavender background. Branches are drawn to scale based on the number of CNA events. Chromosomal aberrations associated to the branch with the largest HG clone are shown. Red indicates gains and blue losses. Patient IDs highlighted in red indicate cases with coexisting PDAC. SNVs associated with each branch are labeled. Red arrow labels the branch with larger HG clone.


HHS | National Institutes of Health (NIH)

Deutsche Forschungsgemeinschaft (DFG)

UU | Huntsman Cancer Institute, University of Utah (HCI)

Tobacco-Related Disease Research Program (TRDRP)



Intraductal papillary mucinous neoplasms (IPMN) are cystic precursor lesions to pancreatic ductal adenocarcinoma (PDAC). IPMNs undergo multistep progression from low-grade (LG) to high-grade (HG) dysplasia, culminating in invasive neoplasia. While patterns of IPMN progression have been analyzed using multiregion sequencing for somatic mutations, there is no integrated assessment of molecular events, including copy-number alterations (CNA) and transcriptional changes that accompany IPMN progression. We performed laser capture microdissection on surgically resected IPMNs of varying grades of histologic dysplasia obtained from 23 patients, followed by whole-exome and whole-transcriptome sequencing. Overall, HG IPMNs displayed a significantly greater aneuploidy score than LG lesions, with chromosome 1q amplification being associated with HG progression and with cases that harbored co-occurring PDAC. Furthermore, the combined assessment of single-nucleotide variants (SNV) and CNAs identified both linear and branched evolutionary trajectories, underscoring the heterogeneity in the progression of LG lesions to HG and PDAC. At the transcriptome level, upregulation of MYC-regulated targets and downregulation of transcripts associated with the MHC class I antigen presentation machinery as well as pathways related to glycosylation were a common feature of progression to HG. In addition, the established PDAC transcriptional subtypes (basal-like and classical) were readily apparent within IPMNs. Taken together, this work emphasizes the role of 1q copy-number amplification as a putative biomarker of high-risk IPMNs, underscores the importance of immune evasion even in noninvasive precursor lesions, and reinforces that evolutionary pathways in IPMNs are heterogenous, comprised of both SNV and CNA-driven events. Integrated molecular analysis of genomic and transcriptomic alterations in the multistep progression of IPMNs, which are bona fide precursors of pancreatic cancer, identifies features associated with progression of low-risk lesions to high-risk lesions and cancer, which might enable patient stratification and cancer interception strategies.